Lenalidomide for second-line treatment of advanced hepatocellular cancer: A brown university oncology group phase II study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 1, 2015, Pages 1-4

  Safran, Howard ^a   Charpentier, Kevin P ^a   Kaubisch, Andreas ^b   Mantripragada, Kalyan ^a   Dubel, Gregory ^a   Perez, Kimberly ^a   Faricy Anderson, Katherine ^a   Miner, Thomas ^a   Eng, Yoko ^b   Victor, Joel ^b   Plette, Angela ^a   Espat, Joseph ^a   Bakalarski, Pamela ^a   Wingate, Patti ^a   Berz, David ^a   Luppe, Denise ^a   Martel, Diane ^a   Rosati, Kayla ^a   Aparo, Santiago ^b  

^a MIRIAM HOSPITAL   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

hepatocellular cancer; Lenalidomide; sorafenib

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; LENALIDOMIDE; SORAFENIB;

ABDOMINAL INFECTION; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ARTICLE; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILD PUGH SCORE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; FAINTNESS; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPATITIS B; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPONATREMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MUSCLE WEAKNESS; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PRURITUS; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY;

EID: 84964211517     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182868c66     Document Type: Article

References (25)

1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
2. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23:6657-6663.
3. Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is antiangiogenic in vivo and inhibits endothelial cell migration and akt phosphorylation in vitro. Microvasc Res. 2005;69:56-63.
4. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-Angiogenic activity independently of immunomodulatory effects. Br J Cancer. 2002;87:1166-1172.
5. Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs sultan cells and angiogenesis in vivo. Leukemia. 2003;17:41-44.
6. Marriott JB, Dredge K, Dalgleish AG. Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents. Curr Drug Targets Immune Endocr Metabol Disord. 2003;3:181-186.
7. Chanan-Khan AA, Padmanabhan S, Miller KC, et al. In vivo evaluation of immunomodulating effects of lenalidomide (L) on tumor cell microenvironment as a possible underlying mechanism of the antitumor effects observed in patients with chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts. 2005;106:2975.
8. Gandhi AK, Kang J, Naziruddin S, et al. Lenalidomide inhibits proliferation of namalwa CSN. 70 cells and interferes with gab1 phosphorylation and adaptor protein complex assembly. Leuk Res. 2006;30:849-858.
9. Chanan-Khan A, Ersing N, Krammer D, et al. Pro-Apoptotic effect of lenalidomide in patients with chronic lymphocytic leukemia is possibly mediated through interruption of the phosphatidylinositol pathway. Blood. 2006;108:2102.
10. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-Alpha. J Immunol. 1999;163:380-386.
11. Chang DH, Liu N, Klimek V, et al. Enhancement of liganddependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006;108:618-621.
12. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005;128: 192-203.
13. Bjorklund CC, Ma W, Wang ZQ, et al. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011;286: 11009-11020.
14. Kaur P, Mani S, Cros MP, et al. Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma. Tumor Bio. 2012;33:325-336.
15. Hendaoui I, Lavergne E, Lee HS, et al. Inhibition of Wnt/betacatenin signaling by a soluble collagen-derived frizzled domain interacting with Wnt3a and the receptors frizzled 1 and 8. PLos One. 2012;7:e30601.
16. Anson M, Crain-Denoyelle AM, Baud V, et al. Oncogenic betacatenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest. 2012;122:586-599.
17. Kaur P, Mani S, Cros MP, et al. Epigeneic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma. Tumour Biol. 2012;33:325-336.
18. Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharm Exp Therapeutics. 2003;305:1222-1232.
19. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326-2335.
20. Azad A, Chionh F, Cebon J, et al. Targeted agents for the systemic treatment of advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2009;5:76-86.
21. Patt YZ, Brown TD, Hassan MM, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 2005;103:749-755.
22. Lin AY, Levitt L, Brophy N, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer. 2005;103:119-125.
23. Hsu C, Chen CN, Chen LT, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology. 2003;65: 242-249.
24. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-322.
25. Marriott JB, Muller G, Stirling D, et al. Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther. 2001;1:675-682.